Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Sep 13 - Sep 18
10.1210/clinem/dgae298 J Clin Endocrinol Metab
It belongs to a novel class of drugs known as triple agonists , meaning it simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1) which reduces appetite and slows gastric emptying [9] [10] GIP (glucose-dependent insulinotropic polypeptide) which may enhance insulin secretion and has been suggested in early studies to support fat metabolism Glucagon receptor which may increase energy expenditure and has been proposed to support fat breakdown in the liver, based on early pharmacological data [11] [12] This triple mechanism distinguishes retatrutide from existing approved medicines such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist)
$350 $245 $149: The GLP-1 Price War Has Begun The GLP-1 Price Collapse: What It Means for You, Patients & the Future of Cardiometabolic Health Why Im writing this now and why it matters for every clinic visit this month
All aspects, desired but also unwanted effects of these drugs must be presented to the patients, and active cooperation is necessary
The ESSENCE trial 240-week readout in 2028 will be a landmark, but longer follow-up and adequately powered studies in higher-risk populations (F3-F4 fibrosis) remain priorities
The injectable vs oral peptides comparison explains why bioavailability matters so much
